Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
MEDFORD, N.Y., Feb. 22, 2018 -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2017 after the close of trading on Thursday, March 8, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by dialing 877-407-0778 from the US or 201-689-8565 from outside the US. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at www.chembio.com. A telephone replay will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 26056 until 4:30pm ET on Thursday, March 15, 2018.
Contact:
Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
[email protected]
